Clinical trials: Patients With Major Depressive Disorder
Depressive Disorder, Treatment-Resistant
Efficacy, Safety, and Tolerability Study of AVP-786 as an Adjunctive Therapy in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment
The objectives of this 10-week study are to evaluate the efficacy, safety, and tolerability of AVP 786 as an adjunctive therapy compared with placebo in patients with major depressive disorder (MDD) who have shown an inadequate…
- Trial name
- NCT02153502
- Testing
- AVP-786 (d6-dextromethorphan hydrobromide and quinidine sulfate combination)
- Where
- 32 sites in United States
- Volunteers
- 206 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Major Depressive Disorder
Clinical Trial of the Effectiveness of Metacognitive Therapy in the Treatment of Patients With Major Depressive Disorder
The main aim of this study is to (1) evaluate the effectiveness of metacognitive therapy for major depressive disorder. Additional aims are to (2) investigate patterns of change and the mechanisms of action involved during…
- Trial name
- NCT01608399
- Testing
- Metacognitive therapy
- Where
- Norway
- Volunteers
- 40 people
- Sponsor
- Norwegian University of Science and Technology
Major Depressive Disorder
A Phase 3 Study of Lu AA21004 in Patients With Major Depressive Disorder
The purpose of this study is to evaluate the efficacy of two fixed doses of vortioxetine (Lu AA21004; 10 or 20 mg/day) after 8 weeks of treatment in patients with major depressive disorder (MDD) in Japan.
- Trial name
- NCT02389816
- Testing
- Vortioxetine
- Where
- 47 sites in Japan
- Volunteers
- 493 people
- Sponsor
- Takeda
Bipolar Disorder, Major Depressive Disorder
The Gut Microbiota of Bipolar and Depression
Background: The gut microbiome is emerging as an important factor in regulating mental health yet it remains unclear what the target should be for psychiatric treatment.
- Trial name
- NCT03062332
- Testing
- Faecal genome
- Where
- China
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Depression, Anhedonia
PRISM Neurofeedback Training for MDD Anhedonic Patients
The goal of this interventional double-blind study is to demonstrate the safety and efficacy of PRISM neurofeedback training within an MDD Anhedonia sample. The goals of this study include: 1.
- Trial name
- NCT05869708
- Testing
- Active RS-EFP
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- GrayMatters Health Ltd.
Depression Unipolar, Insomnia
Mental and Psychological Problems and Insomnia Disorder of Medical Staff in Hospital With Infected COVID-19 Patients
The objective of this study is to clarify the severity of psychological problems and insomnia and the two's relationship with time of hospital medical staff in hospital where its staff are infected with COVID-19.
- Trial name
- NCT04978220
- Where
- China
- Volunteers
- 390 people
- Sponsor
- Peking University Sixth Hospital
Major Depressive Disorder
Pentoxifylline as an Adjunct to Citalopram in Adult Patients With Major Depressive Disorder
The aim of this study is to test if combining the antidepressant Citalopram with Pentoxifylline (PTX), a medicine with anti-inflammatory and phosphodiesterase inhibitory properties, enhanced antidepressant efficacy in adult…
- Trial name
- NCT05271084
- Testing
- Citalopram (tablet) 20 mg + Pentoxifylline (tablet) 400Mg
- Where
- Iraq
- Volunteers
- 100 people
- Sponsor
- Hawler Medical University
Major Depressive Disorder, Depression
A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder (MDD)
The purpose of this study is to determine if TC-5214 or placebo (a tablet that looks like medicine tablet or capsule, but contains no active medicine) is safe and effective when taken together with another antidepressant.
- Trial name
- NCT01157078
- Testing
- TC-5214
- Where
- 51 sites in United States, India
- Volunteers
- 319 people
- Sponsor
- AstraZeneca
Major Depressive Disorder (MDD), Hypovitaminosis D
Effect of Vitamin D Supplementation on Brain Waves in Female Major Depressive Disorder Patients With Hypovitaminosis D
Major Depressive Disorder (MDD) is a common mood disorder characterized by persistent sadness, loss of interest and cognitive impairment.
- Trial name
- NCT07579078
- Testing
- Dietary vitamin D
- Where
- Bangladesh
- Volunteers
- 34 people
- Sponsor
- Bangladesh Medical University
Major Depression
Effects of Deep Brain Stimulation in Treatment Resistant Major Depression
The investigators will investigate in a sham controlled design antidepressant effects and safety of DBS to the superolateral branch of the main medial forebrain bundle (slMFB).
- Trial name
- FORESEE (NCT01095263)
- Testing
- DBS
- Where
- Germany
- Volunteers
- 7 people
- Sponsor
- University Hospital, Bonn
Major Depressive Disorder
BTRX-246040 Administered Once Daily to Patients With Major Depressive Disorder
This study will determine the efficacy, safety, and tolerability of a once-daily (QD) dose of up to 80 mg of BTRX-246040 for 8 weeks in participants with MDD.
- Trial name
- NCT03193398
- Testing
- BTRX-246040 oral capsule(s)
- Where
- 8 sites in United States
- Volunteers
- 104 people
- Sponsor
- BlackThorn Therapeutics, Inc.
Depressive Disorder, Major
Efficacy and Safety Study of Vortioxetine (Lu AA21004) for Treatment of Major Depressive Disorder
The purpose of this study is to assess the efficacy and safety of multiple doses of vortioxetine, once daily (QD), in participants with major depressive disorder.
- Trial name
- NCT01255787
- Testing
- Vortioxetine
- Where
- 70 sites in Croatia, Finland and 14 more
- Volunteers
- 600 people
- Sponsor
- Takeda
Major Depressive Disorder
A Study of LY2216684 in Participants With Major Depression Disorder
The primary objective of this study is to evaluate the long-term safety and tolerability of LY2216684 administered once daily in the adjunctive treatment with an Selective Serotonin Reuptake Inhibitors (SSRI) for up to…
- Trial name
- NCT01370499
- Testing
- LY2216684, SSRI
- Where
- 9 sites in Japan
- Volunteers
- 288 people
- Sponsor
- Eli Lilly and Company
Atrial Fibrillation (AF), Depression - Major Depressive Disorder
A Precision Medicine Approach to the Prevention of Depression in Patients With Atrial Fibrillation
The purpose of the proposed project is to test a new therapist-assisted, eHealth intervention (HOPE-AF) targeted to prevent depression in patients with atrial fibrillation (AF). AF is the most common sustained cardiac arrhythmia.
- Conditions
- Atrial Fibrillation (AF), Depression - Major Depressive Disorder, Anxiety
- Trial name
- HOPE-AF (NCT07178691)
- Testing
- Online psychological intervention
- Where
- 3 sites in Denmark
- Volunteers
- 28 people
- Sponsor
- University of Southern Denmark
Major Depressive Disorder
Optimize and Predict Antidepressant Efficacy for Patient With MDD Using Multi-omics Analysis and AI-predictive Tool
OPADE is a non-profit, observational, multicenter, open-label study aimed at defining personalized treatment for Major Depressive Disorder (MDD).
- Trial name
- OPADE (NCT06550037)
- Where
- Italy
- Volunteers
- 350 people
- Sponsor
- Alessio Fasano
Major Depressive Disorders
Efficacy and Safety of One Single Dose of SR58611 Compared to Placebo and Paroxetine
Primary objective is to demonstrate the antidepressant efficacy on the Hamilton depression rating scale (HAM-D) of amibegron (SR58611) 700 mg/day compared to placebo in the treatment of patients with a recurrent major depressive…
- Trial name
- NCT00825019
- Testing
- amibegron (SR58611A), paroxetine
- Where
- United States
- Volunteers
- 306 people
- Sponsor
- Sanofi
Unipolar Depression
Ketamine Trial for the Treatment of Depression
This study is a Randomized Controlled Trial, investigating the safety and efficacy of administration of ketamine as a potential treatment for depression.
- Trial name
- NCT02401139
- Testing
- Ketamine
- Where
- 2 sites in Australia
- Volunteers
- 10 people
- Sponsor
- The University of New South Wales
Major Depressive Disorder, Treatment Resistant Depression
Comparing Quetiapine XR Monotherapy and Augmentation With Lithium Augmentation in TRD Patients
The primary objective of the study is to evaluate the efficacy of Quetiapine extended release (XR) in combination with an selective serotonin reuptake inhibitor (SSRI) or Venlafaxine versus Lithium in combination with an…
- Trial name
- RUBY (NCT00789854)
- Testing
- Quetiapine XR, Lithium carbonate, SSRI/Venlafaxine
- Where
- 106 sites in Australia, Austria and 11 more
- Volunteers
- 688 people
- Sponsor
- AstraZeneca
Major Depressive Disorder
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-061)
A clinical study to determine the efficacy and safety of an Treatment of MK0869 in the treatment of depression.
- Trial name
- NCT00035295
- Testing
- MK0869, aprepitant
- Volunteers
- 584 people
- Sponsor
- Merck Sharp & Dohme LLC
Depressive Disorder, Major
A Study in People With Depression to Test the Effects of BI 1358894 on Parts of the Brain That Are Involved in Emotions
To assess the effect of a single dose of BI 1358894 compared to placebo on BOLD responses in modulating brain processing of emotional and cognitive stimuli on the amygdala and related brain structure using fMRI in in unmedicated…
- Trial name
- NCT03854578
- Testing
- BI 1358894, Citalopram
- Where
- Germany
- Volunteers
- 73 people
- Sponsor
- Boehringer Ingelheim